Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M (Cloretazine) in patients (pts) with first relapse of acute myeloid leukemia (AML)

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M (Cloretazine) in patients (pts) with first relapse of acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO). 2008; in press.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.